Ekso Bionics Holdings (Ekso Bionics Holdings) Cash-to-Debt : 1.21 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Ekso Bionics Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ekso Bionics Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.21.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ekso Bionics Holdings could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Ekso Bionics Holdings's Cash-to-Debt or its related term are showing as below:

EKSO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.21 Med: 3.07 Max: 614.39
Current: 1.21

During the past 12 years, Ekso Bionics Holdings's highest Cash to Debt Ratio was 614.39. The lowest was 1.21. And the median was 3.07.

EKSO's Cash-to-Debt is ranked worse than
58% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs EKSO: 1.21

Ekso Bionics Holdings Cash-to-Debt Historical Data

The historical data trend for Ekso Bionics Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ekso Bionics Holdings Cash-to-Debt Chart

Ekso Bionics Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

2.81

3.34

18.19

2.74

1.21

Ekso Bionics Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															2.74	2.17	1.77	1.33	1.21

Competitive Comparison of Ekso Bionics Holdings's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Ekso Bionics Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ekso Bionics Holdings's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ekso Bionics Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ekso Bionics Holdings's Cash-to-Debt falls into.

Ekso Bionics Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ekso Bionics Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	8.638	/	(1.613	+	5.555)
	=	1.21

Ekso Bionics Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	8.638	/	(1.613	+	5.555)
	=	1.21

Ekso Bionics Holdings (NAS:EKSO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ekso Bionics Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ekso Bionics Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ekso Bionics Holdings (Ekso Bionics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ekso Bionics Holdings Inc (NAS:EKSO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

23E2:Germany

Address

101 Glacier Point, Suite A, San Rafael, CA, USA, 94901

Website

https://www.eksobionics.com

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The regions company operates in are the Americas, EMEA, and APAC.

Executives

Jerome Wong	officer: Interim CFO	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Scott G. Davis	officer: President & COO	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Steven Sherman	director
Jason C Jones	officer: VP of Product Development	EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
John Glenn	officer: Chief Financial Officer	7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
Lathan Corinna	director	140 KENDRICK STREET, NEEDHAM MA 02494
William R Shaw	officer: See Remarks	1414 HARBOUR WAY SOUTH, SUITE 1201, C/O EKSO BIONICS HOLDINGS, INC., RICHMOND CA 94804
Rhonda A. Wallen	director	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Mary Ann Cloyd	director	184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Combest Development (hong Kong) Ltd	10 percent owner	ROOM 2210, CC WU BUILDING 302, HENNESSY ROAD, WAN CHAI, HONG KONG K3 999077
Jack Peurach	director, officer: Chief Executive Officer	1414 HARBOUR WAY SOUTH, SUITE 1201, RICHMOND CA 94804
Thomas A Schreck	director	10240 BUBB RD, CUPERTINO CA 95014
Puissance Capital Management Lp	10 percent owner	950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Christian Babini	officer: VP of Sales, Americas	C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1, RICHMOND CA 94804
Puissance Cross-border Opportunities Ii Llc	10 percent owner	C/O PUISSANCE CAPITAL FUND (GP) LLC, 950 THIRD AVENUE, NEW YORK NY 10022